AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson ' s Disease

If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs Submission is supported by Phase 3 study that demonstrated patients had significant increases in hours of " On " time without...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news